January 31, 2024 · Form 4 insider transaction
Anzalone Christopher Richard bought 57,499 shares of Arrowhead Pharmaceuticals, Inc. at $14.54 per share, a transaction worth $836.0K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.